Lauren Gilstrap

Lauren Gilstrap

Auto-generated profile, based on publicly available information

Lauren Gilstrap

Heart and Vascular Center, Dartmouth Hitchcock Medical Center The Dartmouth Institute, Geisel School of Medicine at Dartmouth Lebanon NH USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
LGLauren Gilstrap
Lauren Gilstrap
WZWeiping Zhou
Weiping Zhou
MAMarcella Alsan
Marcella Alsan
ANAnoop Nanda
Anoop Nanda
JSJonathan S. Skinner
Jonathan S. Skinner
In 2020, COVID-19 abruptly altered the delivery of health care and the daily operations of nursing facilities.1 Changes in health care delivery included a decrease in inpatient care2,3 and a transition of outpatient care to telehealth platforms.4 Changes in nursing facility operations included lockdowns and strict visitation procedures, resulting in social isolation for many residents.5-7 The association between those secondary changes related to the pandemic and patient outcomes, especially among vulnerable populations, has not been well described.

27 April 2022 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
JPJohn R. Power
John R. Power
JAJoachim Alexandre
Joachim Alexandre
ACArrush Choudhary
Arrush Choudhary
BOBenay Ozbay
Benay Ozbay
SHSalim S. Hayek
Salim S. Hayek
MPMilan Patel
Milan Patel

2 August 2019 in JAMA Network Open
Verified
Journal Article
Open access
LGLauren G. Gilstrap
Lauren G. Gilstrap
MCMichael E. Chernew
Michael E. Chernew
CNChristina A. Nguyen
Christina A. Nguyen
SASartaj Alam
Sartaj Alam
BBBarbara Bai
Barbara Bai
MLMary Beth Landrum
Mary Beth Landrum
Clinical practice group performance on quality measures associated with chronic disease management has become central to reimbursement. Therefore, it is important to determine whether commonly used process and disease control measures for chronic conditions correlate with utilization-based outcomes, as they do in acute disease. To examine the associations among clinical practice group performance on diabetes quality measures, including process measures, disease control measures, and utilization-based outcomes. This retrospective, cross-sectional analysis examined commercial claims data from a national health insurance plan. A cohort of eligible beneficiaries with diabetes aged 18 to 65 years who were enrolled for at least 12 months from January 1, 2010, through December 31, 2014, was defined. Eligible beneficiaries were attributed to a clinical practice group based on the plurality of their primary care or endocrinology office visits. Data were analyzed from October 1, 2018, through April 30, 2019. For each clinical practice group, performance on current diabetes quality measures included 3 process measures (2 testing measures [hemoglobin A1c {HbA1c} and low-density lipoprotein {LDL} testing] and 1 drug use measure [statin use]) and 2 disease control measures (HbA1c <8% and LDL level <100 mg/dL). The rates of utilization-based outcomes, including hospitalization for diabetes and major adverse cardiovascular events (MACEs), were also measured. In this cohort of 652 258 beneficiaries with diabetes from 886 clinical practice groups, 42.9% were aged 51 to 60 years, and 52.6% were men. Beneficiaries lived in areas that were predominantly white (68.1%). At the clinical practice group level, except for high correlation between the 2 testing measures, correlations among different quality measures were weak (r range, 0.010-0.244). Rate of HbA1c of less than 8% had the strongest correlation with hospitalization for MACE (r = -0.046; P = .03) and diabetes (r = -0.109; P < .001). Rates of HbA1c control at the clinical practice group level were not significantly associated with likelihood of hospitalization at the individual level. Performance on the process and disease control measures together explained 3.9% of the variation in the likelihood of hospitalization for a MACE or diabetes at the individual level. In this study, performance on utilization-based measures-intended to reflect the quality of chronic disease management-was only weakly associated with direct measures of chronic disease management, namely, disease control measures. This correlation should be considered when determining the degree of financial emphasis to place on hospitalization rates as a measure of quality in treatment of chronic diseases.

1 May 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
LGLauren G. Gilstrap
Lauren G. Gilstrap
RBRachel A. Blair
Rachel A. Blair
HHHaiden A. Huskamp
Haiden A. Huskamp
KZKatya Zelevinsky
Katya Zelevinsky
SNSharon-Lise Normand
Sharon-Lise Normand
In 2015, more than 30 million Americans, almost 10% of the adult population, had diabetes. An additional 1.5 million new cases were being diagnosed annually, the vast majority of which were new cases of type 2 diabetes.1 Recent work investigating the factors associated with increased health care spending over the past 17 years found that among all chronic diseases, diabetes had the largest increase in annual spending from 1996 to 2013—an increase of $64 billion, $44 billion (69%) of which was spent on prescription drugs.2

7 June 2021 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
LGLauren Gilstrap
Lauren Gilstrap
AAAndrea M. Austin
Andrea M. Austin
AOA. James O’mAlley
A. James O’mAlley
BGBarbara Gladders
Barbara Gladders
ABAmber E. Barnato
Amber E. Barnato
JSJonathan Skinner
Jonathan Skinner

1 March 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
RMRonson J. Madathil
Ronson J. Madathil
LGLauren G. Gilstrap
Lauren G. Gilstrap
MPMarc P. Pelletier
Marc P. Pelletier
MMMandeep Mehra
Mandeep Mehra